Microencapsulation technology for stable hydrophobic liquid dispersion in water
NanoStar Pharmaceuticals has developed a microencapsulation technology that enables the stable dispersion of hydrophobic oils in water by coating micronized droplets with polysaccharides. This enhances release kinetics and encapsulation efficiency, ideal for pharmaceutical and cosmetic applications.
Overview
NanoStar Pharmaceuticals presents a cutting-edge microencapsulation technology designed to stabilize hydrophobic liquids, such as oils, in water. This is achieved by forming micronized oil droplets coated with a thin film of polysaccharide at the oil-water interface. By adjusting the polysaccharide concentration, the size of the oil droplets can be controlled, thereby enhancing the release kinetics of the encapsulated active ingredients. This technology is particularly beneficial for industries requiring precise control over release profiles and encapsulation efficiency, such as pharmaceuticals and cosmetics.
Technical specifications
Key features:
- Utilizes polysaccharide coatings to stabilize oil droplets in water
- Adjustable polysaccharide concentration to control droplet size and release kinetics
- Achieves encapsulation efficiencies greater than 90%
- Micronized droplets ensure a stable dispersion in aqueous environments
Application process:
- Polysaccharides and active ingredients are mixed and triturated to form a homogeneous mixture
- Water is added to create a stable suspension
- Formulations are evaluated for encapsulation efficiency and droplet size using microscopy
- Release kinetics studied through a dialyzing process against a tween20-supplemented water solution
Technology readiness level
This microencapsulation technology is currently at Technology Readiness Level 3, indicating that it has been demonstrated in a laboratory environment with plans for further validation and optimization in real-world applications.
About NanoStar Pharmaceuticals
NanoStar Pharmaceuticals is a biotechnology company that specializes in advanced drug delivery technologies. The company designs and optimizes proprietary platforms, including liposomes and lipid nanoparticles (LNP), to overcome critical challenges in drug development such as poor solubility, low permeability, and poor stability. By utilizing sophisticated engineering and materials science, NanoStar creates innovative formulations for small molecules, proteins, and nucleic acids, enabling targeted delivery to specific cells and tissues. Their research and development efforts are supported by a multidisciplinary team with expertise in pharmacology, bioinformatics, and AI, aimed at developing next-generation therapeutics for diseases with limited treatment options.
As a preclinical contract research organization (CRO), NanoStar provides comprehensive development solutions to partners and clients, helping them accelerate therapeutic candidates from early-stage formulation to preclinical validation. Their services encompass formulation development, characterization, scale-up, and a suite of cell-based, in vitro, and animal studies to assess safety, efficacy, and pharmacokinetics. By addressing unmet formulation needs and providing customized preclinical support, the company enables the transformation of drugs with significant delivery hurdles into safe and effective treatments, with a particular focus on pediatric formulations, cancer immunotherapy, gene therapy, and transdermal delivery applications.
Inquire about this partnering listing
Industry applications
delivered to your inbox.